Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.73 |
| ▸ | LTA4H | P09960 | 1/20 | 0.68 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928796 | 1.00 | ANPEP (1.00) | ANPEPEPHX1LTA4HENPEPMMP2 | |
| SCHEMBL6805553 | 1.00 | ANPEP (1.00) | ANPEPEPHX1LTA4HENPEPMMP2 | |
| Hydrochloric Acid SCHEMBL5409548 | 0.98 | ANPEP (0.95) | ANPEPEPHX1LTA4HENPEPMMP2 | |
| SCHEMBL28656 | 0.85 | EPHX1 (1.00) | ANPEPEPHX1MMP2SLC6A2TAAR1 | |
| SCHEMBL1893281 | 0.82 | LTA4H (1.00) | ANPEPLTA4HSLC6A2MAOASLC6A3 | |
| SCHEMBL29399745 | 0.82 | LTA4H (1.00) | ANPEPLTA4HSLC6A2MAOASLC6A3 | |
| SCHEMBL1893279 | 0.82 | LTA4H (1.00) | ANPEPLTA4HSLC6A2MAOASLC6A3 | |
| Hydrochloric Acid SCHEMBL9402300 | 0.82 | EPHX1 (0.94) | ANPEPEPHX1MMP2SLC6A2TAAR1 | |
| SCHEMBL16155879 | 0.82 | ANPEP (0.69) | ANPEPEPHX1LTA4HMMP2SLC6A2 | |
| SCHEMBL859527 | 0.82 | ANPEP (0.69) | ANPEPEPHX1LTA4HMMP2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-9012485-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012485-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| CN-1429111-A | Methods of inhibiting proliferation and inducing apoptosis in cancer cells | CREIGHTON UNIV (US) | 2003-07-09 | — | — | CN | disclosed |
| US-20020128213-A1 | Sixteen-membered macrolide compounds | KOSAN BIOSCIENCES, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020111317-A1 | Sixteen-membered macrolide compounds | KOSAN BIOSCIENCES, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002032916-A2 | SIXTEEN-MEMBERED MACROLIDE COMPOUNDS | KOSAN BIOSCIENCES, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-5455271-A | Using aromatic amine derivitives as mosquito insecticide | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0640114-A1 | SULFUR-VULCANIZED RUBBER COMPOSITION | Akzo Nobel N.V. (NL) | 1995-03-01 | — | — | EP | disclosed |
| CN-1085229-A | The rubber combination of sulfur cross-linking | AKZO NV (NL) | 1994-04-13 | — | — | CN | disclosed |
| WO-1994000420-A1 | NOVEL TIGHT-BINDING INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993023467-A1 | SULFUR-VULCANIZED RUBBER COMPOSITION | AKZO NOBEL N.V. (NL) | 1993-11-25 | — | — | WO | disclosed |
| US-4631270-A | THIOMETHYLENE REPLACEMENTS | RESEARCH CORPORATION (US) | 1986-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | ANPEP 194/4885EPHX1 1634/4885LTA4H 1363/4885 |
| US-20020111317-A1 | Sixteen-membered macrolide compounds | NOP2, NSUN3, MRPS23 | ANPEP 2618/4885EPHX1 2951/4885LTA4H 635/4885 |
| US-20020128213-A1 | Sixteen-membered macrolide compounds | NOP2, NSUN3, MRPS23 | ANPEP 2618/4885EPHX1 2951/4885LTA4H 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.